Background: Despite treatment having improved through intensive surgical procedures and chemotherapy—and more recently, targeted therapies—ovarian cancer is the most fatal female cancer. As such, we wanted to analyze age-specific survival trends for ovarian cancer in Denmark, Finland, Norway and Sweden over the past 50 years, with a special aim of comparing survival development between the age groups. Methods: We modelled survival data from the NORDCAN database for 1-, 5- and conditional 5/1-year relative (between years 1 and 5) survival for ovarian cancer from 1972 to 2021. Results: Young patients had a 70% 5-year survival while the survival was only 30% for the oldest patients. Conditional survival showed that survival between years 1 and 5 did not improve for patients older than 60 years throughout the 50-year period, during which time the gaps between the youngest and the oldest patients widened. Conclusions: Improvement in 1-year survival was so large that it masked the modest development between years 1 and 5, resulting in a widening age disparity in 5-year survival. The current treatment practices, which appear increasingly effective for younger patients, have not helped remedy the large age differences in ovarian cancer survival. Early detection methods and therapeutic innovations are urgently needed, and aged patients need a special focus.
背景：尽管通过强化手术和化疗以及近年来的靶向治疗，卵巢癌的治疗已有所改善，但其仍是女性癌症中致死率最高的类型。因此，我们旨在分析过去50年间丹麦、芬兰、挪威和瑞典卵巢癌的年龄特异性生存趋势，特别关注不同年龄组间生存进展的比较。 方法：我们基于NORDCAN数据库，对1972年至2021年卵巢癌患者的1年、5年及条件性5/1年（第1年至第5年间）相对生存数据进行了建模分析。 结果：年轻患者的5年生存率达70%，而最年长患者的生存率仅为30%。条件性生存分析显示，在50年期间，60岁以上患者在第1年至第5年间的生存率未见改善，且最年轻与最年长患者间的生存差距持续扩大。 结论：1年生存率的显著提升掩盖了第1年至第5年间生存改善的有限性，导致5年生存率的年龄差异日益扩大。当前治疗方案对年轻患者效果逐渐提升，但未能缩小卵巢癌生存率的巨大年龄差异。亟需早期检测方法和治疗创新，并应特别关注老年患者群体。
Survival in Elderly Ovarian Cancer Remains Challenging in the Nordic Countries
肿瘤(癌症)患者之家